DelfaGLP-1 Atlas

Lead sponsor

KeyBioscience AG

3 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

3

Trials led

1

Active

880

Total enrollment

49

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
1
Phase 2
2

Trials by status

Recruiting
1
Completed
1
Terminated
1

Trials led

Efficacy and Safety of KBP-336 in Obese Individuals with OsteoarthritisBMI ≥30Ph 2Recruiting600
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 DiabetesBMI ≥25Ph 2Completed255
A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DMBMI ≥25Ph 1Terminated25